Lambert-Eaton syndrome is a rare autoimmune disease characterized by impaired neuromuscular transmission. The pathogenesis of the disease is due to the production of antibodies to presynaptic P/Q-type calcium channels at the neuromuscular junction, which leads to a decrease in the release of acetylcholine and subsequent muscle weakness. Unlike myasthenia gravis, Lambert-Eaton syndrome is characterized by increased muscle strength after repeated contractions, which is an important diagnostic feature.
History of the disease and interesting historical facts
The disease was first described in 1956 by American neurologists Edward Lambert and Lee Eaton, who conducted a series of studies in patients with lung tumors. It is interesting to note that the syndrome was initially considered a manifestation of paracancerosmatosis, since more than 60% cases were associated with small-cell lung cancer. “The discovery of this syndrome was an important step in understanding the mechanisms of neuromuscular transmission,” notes neurology professor Robert Pearson in his 1965 monograph.
Epidemiology (statistics of disease occurrence)
Lambert-Eaton syndrome occurs at a rate of approximately 3 cases per million population per year. According to a 2020 study by the US National Neuroscience Institute:
- 50-60% cases are associated with small cell lung cancer
- 40-50% patients are over 50 years old
- The ratio of men to women is 3:1
- The median age at diagnosis is 60 years.
Genetic predisposition to this disease
Although Lambert-Eaton syndrome is primarily an acquired disorder, studies have found a possible link to polymorphisms in certain genes:
- HLA-DR3/DR7 – a marker of predisposition to autoimmune diseases
- CTLA4 is a gene that regulates the activity of T-lymphocytes
- PDCD1 is a gene involved in programmed cell death
According to the study by Wang et al., 2018: “Carriers of mutations in the genes of the HLA system have an increased risk of developing the disease.”
Risk factors for the development of this disease
The main risk factors include:
- Smoking and Chronic Lung Disease
- Exposure to carcinogens
- Presence of oncological diseases
- Long-term contact with heavy metals
- Pre-existing autoimmune diseases
Professional activities related to chemicals play a special role.
Diagnosis of this disease
Diagnostics includes a comprehensive examination:
- Main symptoms: proximal muscle weakness, impaired voluntary movement
- Laboratory tests: determination of antibodies to calcium channels
- Radiological examinations: CT/MRI of the chest to rule out tumors
- Electromyography: characteristic changes during nerve stimulation
- Differential diagnosis: exclusion of myasthenia gravis, polymyositis
Treatment
The therapy includes several areas:
- General therapy: normalization of lifestyle, physiotherapy
- Pharmacological treatment: drugs that improve neuromuscular transmission
- Surgical treatment: removal of the primary tumor if present
- Immunotherapy: plasmapheresis, intravenous immunoglobulin
List of drugs used to treat this disease
- 3,4-diaminopyridine
- Pyridostigmine
- Corticosteroids
- Azathioprine
- Cyclophosphamide
Disease monitoring
Monitoring includes regular inspections every 3 months with the following:
- Neurological examination
- Electromyography
- Antibody concentration estimates
- X-ray examination of chest organs
The prognosis depends on the timeliness of diagnosis and the presence of a tumor.
Age-related features of the disease
In young patients, the disease is more benign, often without tumor pathology. In older patients, it is more often associated with lung cancer and has a more severe course. In childhood, the syndrome is almost never encountered.
Questions and Answers
- How quickly does the disease progress? Symptoms usually progress over several weeks or months.
- Is it possible to completely cure the syndrome? With timely treatment, long-term remission can be achieved.
- How often should you undergo examinations? Quarterly monitoring of the condition is recommended.
Advice from Dr. Oleg Korzhikov
"Patients often ask me about the prognosis of the disease. I would like to emphasize that early diagnosis and comprehensive treatment significantly improve the quality of life. Many are interested in physical exercise - it is indicated, but should be dosed. Regarding diet, I recommend a complete diet with sufficient protein content."
